What is the appropriate dosing and monitoring for Vadadustat (brand name Vafseo) in an adult patient with dialysis‑dependent chronic kidney disease?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 17, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Vadadustat (Vafseo) Dosing and Monitoring for Dialysis-Dependent CKD

Start vadadustat at 300 mg orally once daily for all adult patients with dialysis-dependent CKD who have been on dialysis for at least 3 months, regardless of whether they are ESA-naïve or switching from an ESA. 1

Pre-Treatment Requirements

Before initiating vadadustat, you must:

  • Exclude other causes of anemia (vitamin deficiency, chronic inflammation, bleeding) 1
  • Measure baseline hemoglobin 1
  • Assess iron status: Check serum ferritin and transferrin saturation 1
    • Supplement iron when ferritin <100 mcg/L or TSAT <20%
    • Most CKD patients will require supplemental iron during treatment
  • Obtain baseline liver function tests: ALT, AST, and bilirubin 1

Starting Dose

300 mg once daily for all patients 1

  • Take with or without food
  • Swallow whole (do not cut, crush, or chew)
  • Can be given regardless of dialysis timing or type
  • Administer at least 1 hour before oral iron or iron-containing phosphate binders 1
  • Give at least 1 hour before or 2 hours after non-iron-containing phosphate binders 1

Special Considerations When Switching from ESA

When converting from ESA to vadadustat, still start at 300 mg daily 1. During the transition:

  • Consider RBC transfusion or temporary ESA rescue if Hb falls below 9 g/dL
  • If ESA rescue is needed, pause vadadustat and resume when Hb ≥10 g/dL
  • After ESA rescue, wait before resuming vadadustat:
    • 2 days after last epoetin dose
    • 7 days after last darbepoetin alfa dose
    • 14 days after last methoxy polyethylene glycol-epoetin beta dose
  • Resume at prior dose or 150 mg higher than prior dose 1

Monitoring Protocol

Hemoglobin Monitoring

Monitor Hb every 2 weeks after initiation and after each dose adjustment until stable, then at least monthly. 1

Target Hb range: 10-11 g/dL 1

  • Never target Hb >11 g/dL due to increased risk of death, MI, stroke, and thrombosis 1

Liver Function Monitoring

Measure ALT, AST, and bilirubin monthly for the first 6 months, then as clinically indicated. 1

Discontinue vadadustat if:

  • Persistent ALT or AST >3× ULN, OR
  • ALT or AST >3× ULN with bilirubin >2× ULN 1

Dose Titration Algorithm

Adjust dose in 150 mg increments (range: 150-600 mg maximum) 1

When to Increase Dose

  • Increase no more frequently than every 4 weeks if Hb remains below target 1

When to Decrease or Hold Dose

  • If Hb rises >1 g/dL in any 2-week period OR >2 g/dL in 4 weeks: Interrupt or reduce dose 1
  • If Hb exceeds 11 g/dL: Hold vadadustat until Hb ≤11 g/dL, then resume at 150 mg less than prior dose 1
  • Decreases can occur more frequently than increases 1

When to Discontinue

Stop vadadustat after 24 weeks if no clinically meaningful Hb increase is achieved. Investigate alternative causes of inadequate response before restarting. 1

Critical Safety Warnings

Cardiovascular Risk (Black Box Warning)

Vadadustat increases risk of death, MI, stroke, venous thromboembolism, and vascular access thrombosis 1. In the INNO2VATE trials, vadadustat showed a hazard ratio of 1.17 (95% CI 1.01-1.36) for first MACE compared to darbepoetin alfa in pooled analysis 2.

Avoid in patients with:

  • MI, stroke, or acute coronary syndrome within 3 months prior to starting 1
  • Uncontrolled hypertension (absolute contraindication) 1

Counsel patients to seek immediate care for symptoms of MI, stroke, VTE, or access thrombosis. 1

Hepatotoxicity

Hepatocellular injury occurred in <1% of patients in trials, typically within first 3 months 1. All cases resolved after discontinuation.

Clinical Trial Context

The INNO2VATE trials demonstrated that vadadustat achieved Hb target range (10-11 g/dL in US, 10-12 g/dL non-US) in approximately 44-50% of dialysis patients at weeks 40-52, with mean Hb changes of 0.23-0.43 g/dL 2. However, vadadustat showed slightly lower Hb levels compared to darbepoetin alfa (LSMD -0.17 to -0.18 g/dL) 2.

Real-world Japanese surveillance data showed mean Hb increases of 0.18-0.30 g/dL in ESA-switched patients and 0.34-0.90 g/dL in ESA-naïve patients over 12 months 3.

Common Pitfalls to Avoid

  • Do not target Hb >11 g/dL – this substantially increases cardiovascular risk 1
  • Do not increase dose more frequently than every 4 weeks – allow time for erythropoietic response 1
  • Do not co-administer with oral iron or phosphate binders without proper timing separation 1
  • Do not continue beyond 24 weeks without response – investigate hyporesponsiveness 1
  • Do not forget monthly liver monitoring for first 6 months – hepatotoxicity typically occurs early 1

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.